FDA Expects Sharp Drop In Fee-Paying Drug Applications This Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In what could be viewed as an ominous sign of declining pharmaceutical R&D productivity, FDA is predicting a sharp drop-off in fee-paying drug and biologic applications in the current fiscal year